...
首页> 外文期刊>Biochemistry >Structural and Biochemical Studies of the Hedamycin Type II Polyketide Ketoreductase (HedKR): Molecular Basis of Stereo- and Regiospecificities
【24h】

Structural and Biochemical Studies of the Hedamycin Type II Polyketide Ketoreductase (HedKR): Molecular Basis of Stereo- and Regiospecificities

机译:Hedamycin II型聚酮酮酮还原酶(HedKR)的结构和生化研究:立体和区域特异性的分子基础。

获取原文
获取原文并翻译 | 示例
           

摘要

Bacterial aromatic polyketides that include many antibiotic and antitumor therapeutics are biosynthesized by the type II polyketide synthase (PKS), which consists of 5?10 stand-alone enzymatic domains. Hedamycin, an antitumor antibiotic polyketide, is uniquely primed with a hexadienyl group generated by a type I PKS followed by coupling to a downstream type II PKS to biosynthesize a 24-carbon polyketide, whose C9 position is reduced by hedamycin type II ketoreductase (hedKR). HedKR is homologous to the actinorhodin KR (actKR), for which we have conducted extensive structural studies previously. How hedKR can accommodate a longer polyketide substrate than the actKR, and the molecular basis of its regio- and stereospecificities, is not well understood. Here we present a detailed study of hedKR that sheds light on its specificity. Sequence alignment of KRs predicts that hedKR is less active than actKR, with significant differences in substrate/inhibitor recognition. In vitro and in vivo assays of hedKR confirmed this hypothesis. The hedKR crystal structure further provides the molecular basis for the observed differences between hedKR and actKR in the recognition of substrates and inhibitors. Instead of the 94-PGG-96 motif observed in actKR, hedKR has the 92-NGG-94 motif, leading to Sdominant stereospecificity, whose molecular basis can be explained by the crystal structure. Together with mutations, assay results, docking simulations, and the hedKR crystal structure, a model for the observed regio- and stereospecificities is presented herein that elucidates how different type II KRs recognize substrates with different chain lengths, yet precisely reduce only the C9-carbonyl group. The molecular features of hedKR important for regio- and stereospecificities can potentially be applied to biosynthesize new polyketides via protein engineering that rationally controls polyketide ketoreduction.
机译:II型聚酮化合物合酶(PKS)由5?10个独立的酶促结构域组成,可生物合成包括许多抗生素和抗肿瘤治疗剂在内的细菌芳香聚酮化合物。抗癌抗生素聚酮化合物Hedamycin独特地由I型PKS产生的己二烯基引发,然后与下游II型PKS偶联以生物合成24碳聚酮化合物,其C9位置被II型酮霉素酮还原酶(hedKR)降低。 HedKR与放线菌素KR(actKR)同源,我们之前已对其进行了广泛的结构研究。 hedKR如何能比actKR容纳更长的聚酮化合物底物,以及其区域和立体特异性的分子基础尚不清楚。在这里,我们介绍了对hedKR的详细研究,阐明了其特异性。 KR的序列比对预测hedKR的活性不如actKR,在底物/抑制剂识别上有显着差异。 hedKR的体外和体内试验证实了这一假设。 hedKR晶体结构进一步提供了分子基础,用于观察到的hedKR和actKR在识别底物和抑制剂方面的差异。 hedKR取代了actKR中观察到的94-PGG-96母题,而具有92-NGG-94母题,导致显性立体特异性,其分子基础可以由晶体结构来解释。结合突变,分析结果,对接模拟和hedKR晶体结构,本文提供了一种用于观察到的区域和立体特异性的模型,该模型阐明了不同的II型KR如何识别具有不同链长的底物,而仅精确还原了C9-羰基组。通过合理控制聚酮化合物的酮还原作用的蛋白质工程,对区域和立体特异性很重要的hedKR分子特征可潜在地用于生物合成新的聚酮化合物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号